Form 4: Rani Therapeutics CBO Receives Stock Option Grant

Chief Business Officer Kate McKinley was granted 805,500 stock options in Rani Therapeutics Holdings, Inc.

Summary

• Kate McKinley, Chief Business Officer of Rani Therapeutics, received a grant of 805,500 stock options.
• The options have an exercise price of $0.875 per share.
• The grant was issued on June 3, 2026, with an expiration date of June 2, 2036.
• Vesting occurs monthly over a four-year period starting from April 1, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company strategy or financial health.

Positives

• Aligns executive compensation with long-term shareholder value through a four-year vesting schedule.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future performance of the company's stock price relative to the $0.875 exercise price.

Future Outlook

The options vest over a four-year period, indicating a long-term retention strategy for the Chief Business Officer.

Industry Context

StockSavvy.ai notes that equity-based compensation is a standard practice in the biotechnology sector to incentivize executive leadership and align interests with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for executive equity grants in the U.S. biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on a monthly basis over the next four years.

Key Dates

Keywords

Rani Therapeutics, RANI, Form 4, Stock Options, Executive Compensation, Insider Transaction